克拉维酸、舒巴坦、他唑巴坦均含有 β-内酰胺环结构，为不可逆竞争性抑制剂，能抑制除碳青霉烯酶外的大部分 a 类 β-内酰胺酶，但对 b、c、d 类酶 ...

The Global Beta-lactam and Beta-lactamase Inhibitors Market study includes a rounded approach for the market by analysing past data and analysis uncovered from the leading vendors. Overall, the ...

The global beta-lactam and beta-lactamase inhibitors market size was $27,126 million in 2018, and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% from 2019 to 2028.. The ...

Metallo-beta-lactamases were the most frequently identified carbapenem resistance mechanism among Enterobacterales isolates in IHMA global surveillance. August 14, 2023 07:00 AM Eastern Daylight Time.

First-in-human studies of Mk-3402, a pan metallo-beta-lactamase inhibitor to combat antimicrobial resistance. Presented at: ASM Microbe, June 15-19, 2023; Houston.

Report with market evolution powered by AI - The global beta lactam and beta lactamase inhibitors market size is estimated to grow by USD 8.4 billion from 2025-2029, according to Technavio. The ...

Extended-spectrum beta-lactamase-producing Enterobacteriaceae are found in humans, animals, and the environment. The global spread of antimicrobial resistance demands for cross-sectional research to ...

From 2022 to 2028, Global Beta-lactam and Beta-lactamase Inhibitors Market by MarketsandResearch.biz presents an overview of the current development environment as well as the industry’s future growth ...

The antibiotic combines approved beta-lactam cefepime, which is branded by Pfizer as Maxipime, and Venatorx’s beta-lactamase inhibitor taniborbactam.